Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05042765 · ClinicalTrials.gov registry record
Entheogen Resurgence
A clinical trial, sponsored by Vireo Health.
- Completed
- Registry status
- 102
- Enrollment target
NCT05042765: Completed study, sponsored by Vireo Health.
NCT05042765 is a clinical trial that has completed, run by Vireo Health. The registered enrollment target is 102 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05042765 has completed, sponsored by Vireo Health.
- COMPLETED
- Registry status
- 102 participants
- Enrollment target
Study Summary
For the purpose of this anonymous, observational pilot survey, the investigators will define "entheogens" as substances, generally derived from plants, that are ingested in order to impact one's consciousness for therapeutic, religious, or spiritual purposes. This survey will focus on the naturalistic use of entheogens and other substances including kambo, ayahuasca, hapé, bufo, and sananga typically used in specific cultural and spiritual contexts for healing. There are substantial limitations to what the healthcare community knows about the intentions, motivations, experiences, health behaviors, and demographics of people who decide to participate in entheogen therapy centers or retreats and their willingness to participate in future research studies. The primary goal of this observational pilot survey is to collect self-reported, anonymous data from people who have opted to participate in entheogen therapy centers and retreats during the last five (5) years on the topics of their initial intentions, motivations, experiences, demographics, and willingness to participate in future entheogen research. With the support of established therapy and retreat centers, the research team will aim to collect 100 survey responses from unique, unidentified individuals who have participated in some form of entheogen therapy or treatment during the last five (5) years. Those who choose to fill out the survey will be at least 18 years of age, fluent in English, and self-reporting participation in therapy or a retreat which utilized entheogens in a naturalistic setting in the past five (5) years.
Primary Outcome
The primary outcome will be self-reported experiences related to entheogen use in naturalistic retreat and therapeutic settings.
Interventions
- OTHER self-reported entheogen use
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2021-09-16 |
| Est. Completion | 2022-01-12 |
What the finished NCT05042765 record still lists
NCT05042765 is an observational study that tracks outcomes without assigning an intervention. The registered 102 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which self-reported entheogen use is the first listed.
NCT05042765 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05042765 about?
NCT05042765 is a clinical study titled "Entheogen Resurgence". For the purpose of this anonymous, observational pilot survey, the investigators will define "entheogens" as substances, generally derived from plants, that are ingested in order to impact one's consciousness for therapeutic, religious, or spiritual purposes. This survey will focus on the naturalist...
What is the current status of trial NCT05042765?
This trial is currently completed. The enrollment target is 102 participants. The study started on 2021-09-16. Estimated completion is 2022-01-12.
What interventions are being tested in trial NCT05042765?
The interventions under investigation include: self-reported entheogen use (OTHER).
Who is sponsoring clinical trial NCT05042765?
This trial is sponsored by Vireo Health, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03704662 · 102 participants · NA
Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable or Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma
- NCT04174742 · 102 participants
Self Reported Pain in Women While Undergoing Treatment for Non-metastatic Breast Cancer
- NCT04275362 · 102 participants
Gait Analysis of a Lateral-Pivot Design Total Knee Replacement
- NCT04541082 · 102 participants · Phase 1
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI